Lisata Therapeutics (NASDAQ:LSTA) Stock Price Up 4.3% – Here’s Why

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares rose 4.3% during mid-day trading on Wednesday . The company traded as high as $4.04 and last traded at $3.61. Approximately 866,986 shares were traded during mid-day trading, an increase of 391% from the average daily volume of 176,541 shares. The stock had previously closed at $3.46.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LSTA shares. HC Wainwright lowered shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Zacks Research raised shares of Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $15.00.

Lisata Therapeutics Stock Performance

The company’s fifty day moving average price is $3.65 and its 200 day moving average price is $3.49. The firm has a market capitalization of $32.89 million, a price-to-earnings ratio of -1.94 and a beta of 0.81.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Lisata Therapeutics, Inc. will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LSTA. Cerity Partners LLC acquired a new position in Lisata Therapeutics during the 2nd quarter worth $32,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Lisata Therapeutics in the 3rd quarter worth approximately $37,000. SOL Capital Management CO acquired a new stake in shares of Lisata Therapeutics in the 1st quarter worth approximately $61,000. Ground Swell Capital LLC acquired a new stake in shares of Lisata Therapeutics in the 3rd quarter worth approximately $62,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Lisata Therapeutics by 6.1% in the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after acquiring an additional 7,093 shares during the period. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.